Cargando…

Does the Addition of Cetuximab to Radiochemotherapy Improve Outcome of Patients with Locally Advanced Rectal Cancer? Long-Term Results from Phase II Trials

Purpose. The addition of cetuximab to radiochemotherapy (RCT) failed to improve complete response rates in locally advanced rectal cancer (LARC). We report the long-term results in patients treated within two sequential clinical trials. Methods. Patients receiving neoadjuvant RCT using capecitabine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kripp, M., Horisberger, K., Mai, S., Kienle, P., Gaiser, T., Post, S., Wenz, F., Merx, K., Hofheinz, R.-D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4377474/ https://www.ncbi.nlm.nih.gov/pubmed/25861256 http://dx.doi.org/10.1155/2015/273489

Ejemplares similares

Impact of adjuvant chemotherapy on patients with ypT0–2 ypN0 rectal cancer after neoadjuvant chemoradiation: a cohort study from a tertiary referral hospital
por: Galata, Christian, et al.
Publicado: (2018)

Prognostic Impact of mRNA Expression Levels of HER1–4 (ERBB1–4) in Patients with Locally Advanced Rectal Cancer
por: Kripp, Melanie, et al.
Publicado: (2016)

Acute small-bowel toxicity during neoadjuvant combined radiochemotherapy in locally advanced rectal cancer: determination of optimal dose-volume cut-off value predicting grade 2–3 diarrhoea
por: Reis, Tina, et al.
Publicado: (2015)

A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer
por: Willeke, F, et al.
Publicado: (2007)

Expression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy
por: Schwaab, Juliana, et al.
Publicado: (2011)

Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial
por: Ernst, T, et al.
Publicado: (2007)

Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer
por: Dellas, Kathrin, et al.
Publicado: (2013)

The influence of smoking and other risk factors on the outcome after radiochemotherapy for anal cancer
por: Mai, Sabine Kathrin, et al.
Publicado: (2007)

Long-Term Outcome in a Phase II Study of Regional Hyperthermia Added to Preoperative Radiochemotherapy in Locally Advanced and Recurrent Rectal Adenocarcinomas
por: Schem, Baard-Christian, et al.
Publicado: (2022)

RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV
por: Lorenzen, Sylvie, et al.
Publicado: (2020)

Prognostic Significance of Tumor Regression in Locally Advanced Rectal Cancer after Preoperative Radiochemotherapy
por: Omejc, Mirko, et al.
Publicado: (2017)

Treatment of lymphomatous and leukemic meningitis with liposomal encapsulated cytarabine
por: Kripp, Melanie, et al.
Publicado: (2008)

Predictive Factors of the Response of Rectal Cancer to Neoadjuvant Radiochemotherapy
por: Spolverato, Gaya, et al.
Publicado: (2011)

Evaluation of Efficacy and Tolerance of Radical Radiotherapy and Radiochemotherapy in Treatment of Locally Advanced, Unresectable Rectal Cancer
por: Kraszkiewicz, M., et al.
Publicado: (2022)

Radiochemotherapy with or without cetuximab for unresectable esophageal cancer: final results of a randomized phase 2 trial (LEOPARD-2)
por: Rades, Dirk, et al.
Publicado: (2020)

Influence of complete administration of adjuvant chemotherapy cycles on overall and disease-free survival in locally advanced rectal cancer: post hoc analysis of a randomized, multicenter, non-inferiority, phase 3 trial
por: Sandra-Petrescu, Flavius, et al.
Publicado: (2018)

Intensified neoadjuvant radiochemotherapy for rectal cancer enhances surgical complications
por: Schiffmann, Leif, et al.
Publicado: (2013)

Influence of Gender on Radiosensitivity during Radiochemotherapy of Advanced Rectal Cancer
por: Schuster, Barbara, et al.
Publicado: (2021)

Association Between the Cytogenetic Profile of Tumor Cells and Response to Preoperative Radiochemotherapy in Locally Advanced Rectal Cancer
por: González-González, María, et al.
Publicado: (2014)

Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy
por: Negri, F V, et al.
Publicado: (2008)

Identification of potential metabolic biomarkers of rectal cancer and of the effect of neoadjuvant radiochemotherapy
por: Rodríguez-Tomàs, Elisabet, et al.
Publicado: (2021)

High-Risk Clinicopathological and Genetic Features and Outcomes in Patients Receiving Neoadjuvant Radiochemotherapy for Locally Advanced Rectal Cancer
por: del Carmen, Sofía, et al.
Publicado: (2021)

ALDH1 is an independent prognostic factor for patients with stages II–III rectal cancer after receiving radiochemotherapy
por: Deng, Y, et al.
Publicado: (2014)

Radiochemotherapy
Publicado: (1998)

Prognostic value of the micronucleus assay for clinical endpoints in neoadjuvant radiochemotherapy for rectal cancer
por: Dröge, Leif Hendrik, et al.
Publicado: (2021)

CoCStom trial: study protocol for a randomised trial comparing completeness of adjuvant chemotherapy after early versus late diverting stoma closure in low anterior resection for rectal cancer
por: Sandra-Petrescu, Flavius, et al.
Publicado: (2015)

A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer
por: De Vita, F, et al.
Publicado: (2011)

Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: Do we have indications for individual risk stratification?
por: Sprenger, Thilo, et al.
Publicado: (2010)

Evaluation of EGFR inhibitor‐mediated acneiform skin toxicity within the double‐blind randomized EVITA trial: A thorough gender‐specific analysis using the WoMo score
por: Gaiser, Maria R., et al.
Publicado: (2019)

Single nucleotide polymorphism of GSTP1 and pathological complete response in locally advanced rectal cancer patients treated with neoadjuvant concomitant radiochemotherapy
por: Nicosia, Luca, et al.
Publicado: (2018)

Neoadjuvant volumetric modulated arc radiochemotherapy with a simultaneous integrated boost technique compared to standard chemoradiation for locally advanced rectal cancer
por: JANKARASHVILI, Natalia, et al.
Publicado: (2019)

Neoadjuvant radiochemotherapy in the treatment of fixed and semi-fixed rectal tumors. Analysis of results and prognostic factors
por: Ferrigno, Robson, et al.
Publicado: (2006)

Detection of morphologic alterations in rectal carcinoma following preoperative radiochemotherapy based on multiphoton microscopy imaging
por: Li, Lianhuang, et al.
Publicado: (2015)

Possible contribution of IMRT in postoperative radiochemotherapy for rectal cancer: analysis on 1798 patients by prediction model
por: Liu, Wen-Yang, et al.
Publicado: (2016)

Anastomotic Breakdown Five Years After Neoadjuvant Radiochemotherapy and Ultralow Anterior Resection for Rectal Adenocarcinoma
por: Nguyen, Eric, et al.
Publicado: (2020)

Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2022)

AIO LQ-0110: a randomized phase II trial comparing oral doxycycline versus local administration of erythromycin as preemptive treatment strategies of panitumumab-mediated skin toxicity in patients with metastatic colorectal cancer
por: Kripp, Melanie, et al.
Publicado: (2017)

Clinical responses to PD-1 inhibition and their molecular characterization in six patients with mismatch repair-deficient metastatic cancer of the digestive system
por: Hirsch, Daniela, et al.
Publicado: (2020)

Magnetic resonance tumor regression grade (MR-TRG) to assess pathological complete response following neoadjuvant radiochemotherapy in locally advanced rectal cancer
por: Rengo, Marco, et al.
Publicado: (2017)

The Elevated Pre-Treatment C-Reactive Protein Predicts Poor Prognosis in Patients with Locally Advanced Rectal Cancer Treated with Neo-Adjuvant Radiochemotherapy
por: Partl, Richard, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c3vo86p7bt0p1bdldnee9u17fn